# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
The U.S. Supreme Court supports pharmaceutical companies, led by AstraZeneca, in a lawsuit accusing them of funding terrorism i...
Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement in...
GSK Plc has lost out to Pfizer Inc. on a contract to supply millions of doses of its blockbuster RSV vaccine to the UK in a set...
Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...
The FDA has approved Sarepta Therapeutics' Elevidys for treating Duchenne muscular dystrophy in patients aged 4 and older w...
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threat...
Cantor Fitzgerald analyst Louise Chen reiterates Pfizer (NYSE:PFE) with a Overweight and maintains $45 price target.
US Supreme Court upholds 2017 tax on foreign business income, citing Congress' constitutional power to tax. Justices Kavana...